SGS Expands Testing Capabilities at Its Glasgow Facility

Analytical contract service provider SGS announced expanded capabilities and capacity for testing cell banks and routine bulk harvest for vaccines, gene and cell therapies, monoclonal antibodies, and other recombinant protein-based biological medicines at the company’s Glasgow, UK facility.

The £7.6-million ($10-million) investment, supported in part by a Scottish Enterprise Research and Development grant award of £1.7 million ($2.2 million), was announced in a company statement on Jan. 29, 2019.

The investment includes an additional 1200 sq. m. of space, bringing the total to 2400 sq. m. Additional scientific and quality personnel will be hired, the company reported.

The new laboratory will increase the company’s capacity for existing biosafety services and enhanced real-time polymerase chain reaction platforms and SGS will develop and validate cell-based viral detection systems at the site.

Source: SGS